• 제목/요약/키워드: advanced gastric cancer

검색결과 364건 처리시간 0.024초

Gastric Cancer with Peritoneal Tuberculosis: Challenges in Diagnosis and Treatment

  • Alshahrani, Amer Saeed;Lee, In Seob
    • Journal of Gastric Cancer
    • /
    • 제16권2호
    • /
    • pp.111-114
    • /
    • 2016
  • Herein, we report a 39-year-old female patient presenting with gastric cancer and tuberculous peritonitis. The differential diagnosis between advanced gastric cancer with peritoneal carcinomatosis and early gastric cancer with peritoneal tuberculosis (TB), and the treatment of these two diseases, were challenging in this case. Physicians should have a high index of suspicion for peritoneal TB if the patient has a history of this disease, especially in areas with a high incidence of TB, such as South Korea. An early diagnosis is critical for patient management and prognosis. A surgical approach including tissue biopsy or laparoscopic exploration is recommended to confirm the diagnosis.

재발 진행성 위암 환자의 FOLFOX 유발 부작용 개선에 대한 한의 치료 1례 (A Case Report of FOLFOX-induced Adverse Events in a Patient with Recurrent Advanced Gastric Cancer Treated with Korean Medicine)

  • 고명현;양재호;전형준;조종관;이연월;박소정;유화승
    • 대한한방내과학회지
    • /
    • 제41권1호
    • /
    • pp.81-87
    • /
    • 2020
  • Objective: The purpose of this study was to report the clinical effectiveness of Korean medicine treatment on FOLFOX-induced symptoms such as nausea and dizziness in a patient with recurrent advanced gastric adenocarcinoma. Methods: The patient was diagnosed with recurrent advanced gastric cancer and had FOLFOX-induced nausea and dizziness. The patient was treated with Samchulgunbi-tang and Banhasashim-tang for symptom management. The clinical outcomes were measured by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) and a numeral rating scale (NRS). Results: After treatment, the patient's nausea and dizziness were relieved from NRS 9 to 2 and NRS 8 to 2 respectively. During and after treatment, no severe toxicities were detected on laboratory findings. Conclusion: This case study suggests that Samchulgunbi-tang and Banhasashim-tang may relieve symptoms of FOLFOX-induced nausea and dizziness.

절제 불가능한 국소 진행성 위암 환자에서 Taxotere 및 Cisplatin을 이용한 선행 화학 요법제의 투여 후 근치적 절제가 가능했던 2예 (Curative Resection of Inoperable, Locally Advanced Gastric Cancer after Neoadjuvant Chemotherapy with Taxotere and Cisplatin)

  • 이한홍;허훈;채병주;김욱;전해명
    • Journal of Gastric Cancer
    • /
    • 제5권1호
    • /
    • pp.57-64
    • /
    • 2005
  • 위암의 치료에 있어서 근치적 절제는 완치를 위한 유일한 방법이나 불행이도 많은 환자들이 국소적이나 혹은 타 장기로 전이된 상태로 발견된다. 이런 경우에는 근치적 절제술의 시행이 매우 어렵고 선행 화학요법을 시행하여 병기를 낮추려는 시도가 고려되어야 한다. Docetaxel은 반합성 택산으로 튜불린의 중합 반응을 유도하고 미세관의 해중합 반을을 방해함으로서 그 작용을 나타낸다. 현재 전이성 위암의 신행화학요법에서 docetaxel의 사용이 많이 시도되고 있고 그 반응률이 보고되고 있다. 본 교실에서는 docetsxel과 cisplatin 병용요법을 시행하여 전이성 위암의 부분 관해로 근치적 절제가 가응하였던 2예를 보고하는 바이다.

  • PDF

Preoperative Nodal 18F-FDG Avidity Rather than Primary Tumor Avidity Determines the Prognosis of Patients with Advanced Gastric Cancer

  • Kwon, Hyun Woo;An, Liang;Kwon, Hye Ryeong;Park, Sungsoo;Kim, Sungeun
    • Journal of Gastric Cancer
    • /
    • 제18권3호
    • /
    • pp.218-229
    • /
    • 2018
  • Purpose: This study investigated whether the metabolic avidity of primary tumors and/or metastatic lymph nodes (LNs) measured by $^{18}F$-fluorodeoxyglucose ($^{18}F-FDG$) positron emission tomography/computed tomography (PET/CT) was related to survival after surgery in patients with advanced gastric cancer (AGC). Materials and Methods: One hundred sixty-eight patients with AGC who underwent preoperative $^{18}F-FDG$ PET/CT and curative resection were included. The $^{18}F-FDG$ avidity of the primary gastric tumor and LNs was determined quantitatively and qualitatively. The diagnostic performance of $^{18}F-FDG$ PET/CT was calculated, and the prognostic significance of $^{18}F-FDG$ avidity for recurrence-free survival (RFS) and overall survival (OS) was assessed. Results: In all, 51 (30.4%) patients experienced recurrence, and 32 (19.0%) died during follow-up (median follow-up duration, 35 months; range, 3-81 months); 119 (70.8%) and 33 (19.6%) patients showed $^{18}F-FDG$-avid primary tumors and LNs, respectively. $^{18}F-FDG$ PET/CT showed high sensitivity (73.8%) for the detection of advanced pathologic T ($pT{\geq}3$) stage and high specificity (92.2%) for the detection of advanced pN (${\geq}2$) stage. $^{18}F-FDG$ avidity of LNs was significantly associated with RFS (P=0.012), whereas that of primary tumors did not show significance (P=0.532). Univariate and multivariate analyses revealed that $^{18}F-FDG$ avidity of LNs was an independent prognostic factor for RFS (hazard ratio=2.068; P=0.029). Conclusions: $^{18}F-FDG$ avidity of LNs is an independent prognostic factor for predicting RFS. Preoperative $^{18}F-FDG$ PET/CT can be used to determine the risk and prognosis of patients with AGC after curative resection.

한약에 의한 진행성 위선암의 퇴축에 대한 증례보고 - 8년간의 추적조사를 통한 후향적 증례연구 (A Case of Regression of Advanced Gastric Cancer by Herbal Medicine - A Retrospective Case Study with 8-years Follow-up)

  • 박정석;이연월;조정효;손창규;조종관;유화승
    • 대한한방내과학회지
    • /
    • 제28권1호
    • /
    • pp.193-198
    • /
    • 2007
  • Objective : The aim is to derive further studies evaluating the effectiveness of oriental medical treatment on advanced gastric cancer (AGC) patients. We present a case of a stage IV AGC patient who has survived over 8 years. Methods : We followed up all documents related to the patient. We prescribed to the patient HangAmDan (HAD) three times a day over five years. Abdomen CT was performed to evaluate the therapeutic efficacy. Results : The patient has survived over 8 years. Abdomen CT has shown complete regression. Conclusion : This case may give us the possibility of that oriental medical treatment offers potential benefits for patients with AGC.

  • PDF

진행성 위암에서 육안적 장막침윤의 의의 (Macroscopic Serosal Invasion in Advanced Gastric Cancer)

  • 윤우성;김태봉;유완식
    • Journal of Gastric Cancer
    • /
    • 제6권2호
    • /
    • pp.84-90
    • /
    • 2006
  • 목적: TNM 분류법의 임상적 분류법과 병리학적 분류법은 항상 일치하지는 않는다. 진행성 위암의 육안적 침윤정도 특히 육안적 장막침윤의 의의를 파악하고, 육안적 침윤정도와 병리학적 침윤정도의 일치율을 높일 수 있는 방안을 모색하고자 하였다. 대상 및 방법: 1995년부터 1999년까지 경북대학교병원 외과에서 진행성 위암으로 수술 받은 789명의 환자를 대상으로 하였다. 육안적 및 병리학적 장막침윤 여부에 따른 환자의 예후와 재발양상을 분석하고 육안적 장막침윤과 병리학적 장막침윤이 일치하지 않는 경우는 이에 영향을 주는 인자를 찾았다. 결과: 병리학적 장막침윤에 따른 예후뿐 아니라 육안적 장막침윤에 따른 예후도 유의한 차이를 나타내었다. 육안적 장막침윤이 있는 경우의 42.2%와 병리학적 장막침윤이 있는 경우의 41.4%에서 재발하였으며, 복막재발의 빈도는 19.8% 및 21.9%로 비슷하였다. 육안적 장막침윤 판정의 민감도는 70.3%, 특이도는 77.0%, 양성예측도는 56,4%, 음성 예측도는 86.5%이었다 cT3/ss cancer와 cT3/se cancer와의 비교에서 원격전이 유무 및 육안적 형태에 따라서 유의한 차이를 나타내었고, 다변량 분석에서 두 변수 모두 cT3 cancer가 병리학적으로 ss cancer로 판정될 위험 인자이었다. 결론: 종양이 Borrmann I형이나 II형인 경우와 원격 전이가 없는 경우에는 육안적으로 장막침윤이 있더라도 병리학적으로는 장막침윤이 없을 가능성이 있기 때문에 주의를 요하지만, 위암의 육안적 장막침윤 여부는 환자의 생존율과 근치적 수술 후의 재발양상을 잘 반영하기 때문에 종양학적 가치가 충분하다.

  • PDF

Role of Palliative Surgery in Advanced Gastric Cancer

  • 송교영;공필성;김진조;진형민;김욱;전해명;박승만;안창준;임근우;김승남;박우배;박조현
    • 대한위암학회:학술대회논문집
    • /
    • 대한위암학회 2005년도 제20회 추계학술대회
    • /
    • pp.36-36
    • /
    • 2005
  • PDF

Laparoscopic Gastrectomy and Transvaginal Specimen Extraction in a Morbidly Obese Patient with Gastric Cancer

  • Sumer, Fatih;Kayaalp, Cuneyt;Karagul, Servet
    • Journal of Gastric Cancer
    • /
    • 제16권1호
    • /
    • pp.51-53
    • /
    • 2016
  • Laparoscopic gastrectomy for cancer has some significant postoperative benefits over open surgery with similar oncologic outcomes. This procedure is more popular in the Far East countries where obesity is not a serious public health problem. In the Western countries, laparoscopic gastrectomy for cancer is not a common procedure, yet obesity is more common. Herein, we aimed to demonstrate the feasibility of laparoscopic gastrectomy for advanced gastric cancer in a morbidly obese patient. Additionally, we used natural orifice specimen extraction as an option to decrease wound-related complications, which are more prevalent in morbidly obese patients. In this case, we performed a fully laparoscopic subtotal gastrectomy with lymph node dissection and Roux-en-Y gastrojejunostomy with the specimen extracted through the vagina. To the best of our knowledge, this was the first report of a natural orifice surgery in a morbidly obese patient with gastric cancer.

Validation of Neurotensin Receptor 1 as a Therapeutic Target for Gastric Cancer

  • Akter, Hafeza;Yoon, Jung Hwan;Yoo, Young Sook;Kang, Min-Jung
    • Molecules and Cells
    • /
    • 제41권6호
    • /
    • pp.591-602
    • /
    • 2018
  • Gastric cancer is the fifth most common type of malignancy worldwide, and the survival rate of patients with advanced-stage gastric cancer is low, even after receiving chemotherapy. Here, we validated neurotensin receptor 1 (NTSR1) as a potential therapeutic target in gastric cancer. We compared NTSR1 expression levels in sixty different gastric cancer-tissue samples and cells, as well as in other cancer cells (lung, breast, pancreatic, and colon), by assessing NTSR1 expression via semi-quantitative real-time reverse transcription polymerase chain reaction, immunocytochemistry and western blot. Following neurotensin (NT) treatment, we analyzed the expression and activity of matrix metalloproteinase-9 (MMP-9) and further determined the effects on cell migration and invasion via wound-healing and transwell assays. Our results revealed that NTSR1 mRNA levels were higher in gastric cancer tissues than non-cancerous tissues. Both of NTSR1 mRNA levels and expression were higher in gastric cancer cell lines relative to levels observed in other cancer-cell lines. Moreover, NT treatment induced MMP-9 expression and activity in all cancer cell lines, which was significantly decreased following treatment with the NTSR1 antagonist SR48692 or small-interfering RNA targeting NTSR1. Furthermore, NT-mediated metastases was confirmed by observing epithelial-mesenchymal transition markers SNAIL and E-cadherin in gastric cancer cells. NT-mediated invasion and migration of gastric cancer cells were reduced by NTSR1 depletion through the Erk signaling. These findings strongly suggested that NTR1 constitutes a potential therapeutic target for the inhibition of gastric cancer invasion and metastasis.